TY - JOUR
T1 - Beta-blockers improve survival outcomes in patients with multiple myeloma
T2 - a retrospective evaluation
AU - Hwa, Yi L.
AU - Shi, Qian
AU - Kumar, Shaji K.
AU - Lacy, Martha Q.
AU - Gertz, Morie A.
AU - Kapoor, Prashant
AU - Buadi, Francis K.
AU - Leung, Nelson
AU - Dingli, David
AU - Go, Ronald S.
AU - Hayman, Suzanne R.
AU - Gonsalves, Wilson I.
AU - Russell, Stephen
AU - Lust, John A.
AU - Lin, Yi
AU - Rajkumar, S. Vincent
AU - Dispenzieri, Angela
N1 - Publisher Copyright:
© 2016 The Authors American Journal of Hematology Published by Wiley Periodicals, Inc.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - A preclinical study demonstrated anti-proliferative and apoptotic effect of propranolol on multiple myeloma (MM) cell. Clinical studies suggested that beta-blocker (BB) might impact the prognosis of breast, prostate, colorectal, ovarian, lung, and skin cancer. This retrospective study evaluated the effect of BB in MM disease-specific survival (DSS) and overall survival (OS). Among 1,971 newly diagnosed MM patients seen at Mayo Clinic between 1995 and 2010, usage of BB and other cardiac (or antihypertensive) medications were abstracted. Cumulative incidence function and Kaplan–Meier method were used to estimate 5-year cumulative incidence rate (CIR) of MM death and OS rate, respectively. Nine hundred and thirty (47.2%) patients had no intake of cardiac medications; 260 (13.2%) used BB alone; 343 (17.4%) used both BB/non-BB cardiac medications; and 438 (22.2%) had non-BB cardiac drugs. Superior MM DSS was observed in BB only users, compared to patients without any cardiac drugs (HRCSadj, 0.53, 95% confidence interval [CI], 0.42–0.67, Padj.<0.0001) and non-BB cardiac drugs users (HRCSadj, 0.49, 95% CI, 0.38–0.63, Padj.<0.0001). Patients on both BB and other cardiac drugs showed superior DSS than non-cardiac drugs users (HRCSadj, 0.54, 95% CI, 0.44–0.67, Padj.<0.0001) and non-BB cardiac drug users. (HRCSadj, 0.50, 95% CI, 0.40–0.62, Padj.<0.0001). MM DSS did not differ between BB users with and without other cardiac drugs (Padj.=0.90). Multivariable analysis showed the same pattern for OS. In patients with MM, BB intake is associated with a reduced risk of disease-specific death and overall mortality in comparison to non-BB or no use of cardiac drugs. Am. J. Hematol. 92:50–55, 2017.
AB - A preclinical study demonstrated anti-proliferative and apoptotic effect of propranolol on multiple myeloma (MM) cell. Clinical studies suggested that beta-blocker (BB) might impact the prognosis of breast, prostate, colorectal, ovarian, lung, and skin cancer. This retrospective study evaluated the effect of BB in MM disease-specific survival (DSS) and overall survival (OS). Among 1,971 newly diagnosed MM patients seen at Mayo Clinic between 1995 and 2010, usage of BB and other cardiac (or antihypertensive) medications were abstracted. Cumulative incidence function and Kaplan–Meier method were used to estimate 5-year cumulative incidence rate (CIR) of MM death and OS rate, respectively. Nine hundred and thirty (47.2%) patients had no intake of cardiac medications; 260 (13.2%) used BB alone; 343 (17.4%) used both BB/non-BB cardiac medications; and 438 (22.2%) had non-BB cardiac drugs. Superior MM DSS was observed in BB only users, compared to patients without any cardiac drugs (HRCSadj, 0.53, 95% confidence interval [CI], 0.42–0.67, Padj.<0.0001) and non-BB cardiac drugs users (HRCSadj, 0.49, 95% CI, 0.38–0.63, Padj.<0.0001). Patients on both BB and other cardiac drugs showed superior DSS than non-cardiac drugs users (HRCSadj, 0.54, 95% CI, 0.44–0.67, Padj.<0.0001) and non-BB cardiac drug users. (HRCSadj, 0.50, 95% CI, 0.40–0.62, Padj.<0.0001). MM DSS did not differ between BB users with and without other cardiac drugs (Padj.=0.90). Multivariable analysis showed the same pattern for OS. In patients with MM, BB intake is associated with a reduced risk of disease-specific death and overall mortality in comparison to non-BB or no use of cardiac drugs. Am. J. Hematol. 92:50–55, 2017.
UR - http://www.scopus.com/inward/record.url?scp=85002953384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85002953384&partnerID=8YFLogxK
U2 - 10.1002/ajh.24582
DO - 10.1002/ajh.24582
M3 - Article
C2 - 27733010
AN - SCOPUS:85002953384
SN - 0361-8609
VL - 92
SP - 50
EP - 55
JO - American journal of hematology
JF - American journal of hematology
IS - 1
ER -